<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2640">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480957</url>
  </required_header>
  <id_info>
    <org_study_id>ARCT-021-01</org_study_id>
    <nct_id>NCT04480957</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcturus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcturus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in
      healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blinded (study site staff, subjects and Sponsor), placebo controlled,
      adaptive, ascending dose study evaluating administration of ARCT-021 in healthy adult
      subjects. 0.9% sterile saline will serve as a placebo control. Study drug (ARCT-021 or
      control) will be administered as an intramuscular (IM) injection. The study comprises two
      parts. In the Phase 1 part escalating dose levels given as a single injection to younger
      adults (21 to 55 years) will be evaluated sequentially. Two dose levels will be further
      evaluated in the Phase 2 part of the study in two expansion cohorts in younger adults (21 to
      55 years) and in two elderly subject (56 to 80 years) cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity and dose-relationship of AEs</measure>
    <time_frame>56 days</time_frame>
    <description>Safety and tolerability of ARCT-021 assessed by determining the incidence, severity and dose-relationship of AEs by dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titre for SARS-CoV-2-specific serum neutralizing antibody</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>SARS-CoV-2-specific serum neutralizing antibody levels, expressed as GMT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean titre for SARS-CoV-2-specific serum neutralizing antibody levels</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>SARS-CoV-2-specific serum neutralizing antibody levels, expressed as mean titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise in titre for SARS-CoV-2-spike protein specific neutralizing antibody levels</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>GMFR in titre for SARS-CoV-2-spike protein specific neutralizing antibodies from before vaccination to each subsequent time point</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Increase in SARS-CoV-2--spike protein-specific binding antibody levels</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>GMFR in SARS-CoV-2--spike protein-specific binding antibody levels from before vaccination to each subsequent time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Geometric mean SARS-CoV-2--spike protein-specific binding antibody titre</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>GMT for SARS-CoV-2--spike protein-specific binding antibody levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean SARS-CoV-2--spike protein-specific binding antibody titre</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Mean titer for SARS-CoV-2--spike protein-specific binding antibody levels</description>
  </other_outcome>
  <other_outcome>
    <measure>SARS-CoV-2-specific serum neutralizing antibody seroconversion rate</measure>
    <time_frame>56 days</time_frame>
    <description>Proportion of participants that are seronegative before vaccination achieving a titer of greater than or equal to 20 for SARS-CoV-2-specific serum neutralizing antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>SARS-CoV-2-specific serum neutralizing antibody seroconversion rate (seropositive baseline)</measure>
    <time_frame>56 days</time_frame>
    <description>Proportion of participants that are seropositive before vaccination achieving a greater than or equal to 4-fold rise from before vaccination in SARS-CoV-2-specific serum neutralizing antibody levels</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Escalation Cohort dose 1 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Cohort dose 1 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation Cohort dose 2 of ARCT-021, 21 -55 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Cohort dose 2 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation Cohort dose 3 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Cohort dose 3 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation Cohort dose 4 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Cohort dose 4 of ARCT-021 administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort dose regimen 1, 21 - 55 years.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort dose regimen 2, 21 - 55 years.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort dose regimen 1, 56 - 80 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort dose regimen 1, administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort dose regimen 2, 56 - 80 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion cohort dose regimen 2, administered through 0.5 mL intramuscular injection in the deltoid muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose 1</intervention_name>
    <description>ARCT-021 Dose 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP)</description>
    <arm_group_label>Escalation Cohort dose 1 of ARCT-021, 21 - 55 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose 2</intervention_name>
    <description>ARCT-021 Dose 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021</description>
    <arm_group_label>Escalation Cohort dose 2 of ARCT-021, 21 -55 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose 3</intervention_name>
    <description>ARCT-021 Dose 3 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021</description>
    <arm_group_label>Escalation Cohort dose 3 of ARCT-021, 21 - 55 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose 4</intervention_name>
    <description>ARCT-021 Dose 4 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021</description>
    <arm_group_label>Escalation Cohort dose 4 of ARCT-021, 21 - 55 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose Regimen 1</intervention_name>
    <description>ARCT-021 dose regimen 1 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021</description>
    <arm_group_label>Expansion cohort dose regimen 1, 21 - 55 years.</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 1, 56 - 80 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ARCT-021 Dose Regimen 2</intervention_name>
    <description>ARCT-021 dose regimen 2 is an investigational vaccine comprising a self-replicating (replicon) mRNA that encodes for the prefusion spike protein of 2019-nCoV formulated in a lipid nanoparticle (LNP): ARCT-021</description>
    <arm_group_label>Expansion cohort dose regimen 2, 21 - 55 years.</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 2, 56 - 80 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile 0.9% saline</description>
    <arm_group_label>Escalation Cohort dose 1 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_label>Escalation Cohort dose 2 of ARCT-021, 21 -55 years</arm_group_label>
    <arm_group_label>Escalation Cohort dose 3 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_label>Escalation Cohort dose 4 of ARCT-021, 21 - 55 years</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 1, 21 - 55 years.</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 1, 56 - 80 years</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 2, 21 - 55 years.</arm_group_label>
    <arm_group_label>Expansion cohort dose regimen 2, 56 - 80 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females aged 21 to 80 at the time of informed consent.

          2. Body Mass Index 18-35 kg/m2, inclusive, at screening

          3. Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight
             training, intense aerobics classes etc.) and alcohol for at least 72 hours prior to
             study visits

          4. Temperature is less than 99.3 degrees Fahrenheit (37.4 degrees Celsius) at screening
             AND at the pre-dose evaluation on Day 1

          5. Willing and able to comply with protocol-defined procedures and complete all study
             visits

          6. Males must be surgically sterile or willing to use adequate contraception; females
             must be post-menopausal, surgically sterile or willing to use adequate contraception

        Exclusion Criteria:

          1. Pregnant or breast feeding

          2. Clinically significant abnormalities in medical history

          3. Out of range screening laboratory results

          4. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C
             or chronic hepatitis B

          5. Uncontrolled hypertension (BP &gt; 160/100 mm Hg)

          6. Uncontrolled diabetes

          7. Any history of autoimmune disease

          8. Immunodeficiency of any cause

          9. History of Chronic liver disease

         10. Treatment with another investigational drug, biological agent, or device within one
             month of screening, or 5 half-lives of investigational drug, whichever is longer

         11. Recent (within 1 year) history of, or current drug or alcohol abuse

         12. Has any blood dyscrasias or significant disorder of coagulation

         13. Has an acute illness, as determined by the investigator, with or without fever
             [temperature &gt;38.0 degrees Celsius (100.4 degrees Fahrenheit)] within 72 hours prior
             to each vaccination

         14. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix that has been successfully treated.

         15. Received or plans to receive another vaccine within 4 weeks before study vaccination
             or at any time during the study.

         16. Receipt of any other SARS CoV-2 or other experimental coronavirus vaccine at any time
             prior to study or planned during the study

         17. Have any other conditions, which, in the opinion of the Investigator or Sponsor would
             make the subject unsuitable for inclusion, or could interfere with the subject
             participating in or completing the Study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Low Guek Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SingHealth Investigational Medicine Unit (IMU)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Hughes, MD</last_name>
    <phone>858-900-2660</phone>
    <email>steveh@arcturusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie Crowley</last_name>
    <phone>858-382-1270</phone>
    <email>Connie@arcturusrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SingHealth Investigational Medicine Unit (IMU), Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michellore Aguilar</last_name>
      <phone>+65 6322 7544</phone>
      <email>imu@singhealth.com.sg</email>
    </contact>
    <investigator>
      <last_name>Jenny Low Guek Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

